LONDON (ShareCast) - (ShareCast News) - Biotech company ImmuPharma said Phase III clinical trials of its Lupus treatment, Lupuzor, continued to progress on track and time, with all patients in the study having passed the nine-month stage and 116 patients completing the full 12 months.
The trial has recruited 200 patients for what is the AIM-listed company's lead programme looking at a potential breakthrough compound to treat Lupus, the life threatening auto-immune disease.

The company reported a continued robust safety record, consistent with Lupuzor's product profile as shown in its previous Phase IIb study, as top line results remained on track to be reported in the first quarter of 2018.

Commenting on the trial update, Tim McCarthy, chairman of ImmuPharma said: "Most importantly, we continue to see robust safety within the study which is as equally important as the efficacy profile, in order for Lupuzor to be proactively prescribed by specialists to Lupus patients, who urgently require a more effective treatment for their condition.

"We look forward with confidence to reporting top line results of the study in Q1 2018."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE